BGF, the UK's most active investor in growing businesses, has invested £4m in Evo, a surgical engineering company whose one-day full jaw dental implant treatment could benefit five million people across Britain

evo teeth

Patients with jaw and gum problems have been promised a “new smile” after a surgical engineering company received a £4m investment to improve its full jaw dental implant technology.

London-based Evo’s treatment will use the backing from BGF (Business Growth Fund) to expand its clinics, which feature dental laboratories with the latest hi-tech medical manufacturing tech, across the UK and explore international growth.

The company provides help for patients suffering from severe dental problems caused by gum disease, congenital bone loss or accidents, as well as those who require full jaw reconstruction.

The process features digital scanning, 3D printing and high-precision milling machines with an accuracy on par with aerospace engineering, and was developed in-house by the company’s founder Dr RP Vijayanarayanan – known as Dr Vijay – and his team.

He said: “Evo is taking what’s possible in dentistry today far beyond the limits of what has previously been available.

“We’ve combined state-of-the-art engineering, innovation and first-class patient care to deliver a solution for the chronic types of tooth problems that inflict millions of people across the UK.

“We chose to partner with BGF because of its culture and approach. We have very ambitious expansion plans and wanted to work with someone who will support us longer.”

dental implant
Evo founder Dr R.P. Vijayanarayanan BDS (‘Vijay’)


Evo’s dental implant process can be alternative many don’t know about

Evo has centres in Heathrow and Liverpool and has completed more than 3,000 full-arch reconstructions for patients to date.

The company is able to treat 99% of people who have received a full clinical assessment, including those who may have previously been told their only option is dentures.

The Adult Dental Health survey and Office for National Statistics (ONS) data suggest that more than five million people in the UK could benefit from this treatment.

BGF is the most active and influential investor in small and mid-sized businesses in the UK and has £2.5bn to support a range of growing companies across every region and sector of the economy.

BGF board member Alistair Brew said: “Evo is an example of the best of British craftmanship, engineering and technology.

“The company has built a reputation for clinical excellence and is at the forefront of a nascent, but potentially very large market.

“Led by Dr Vijay, the team has huge ambitions to take this treatment across the UK and internationally, and we’re delighted to be backing them.”